Tag: WuXi Biologics

WuXi Biologics to Expand New Conjugation Solution Center

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it planned to ex...

WuXi Biologics and WuXi Vaccines Entered into Strategic Partnership

wuxi
WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has entered into a st...

First Biologic Company in China Approved by FDA and EMA

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received ...

Chinese and Korean Companies’ Collaboration Expands

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and ABL Bio Corporation (“ABL B...

WuXi on a Way to Have First GMP DS, DP Facilities in China

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the Europe...

WuXi and Amicus are into Exclusive Manufacturing Partnership

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Amicus Therapeutics, a glob...

CANbridge and WuXi Target Rare Genetic Chronic Diseases

CANbridge Pharmaceuticals and WuXi Biologics have expanded their rare disease therapeutics partnership to enable the former to discover, develop and commercialize four additional drug candidates. T...

WuXi Biologics entered into partnership with AC Immune

biopharmaceutical
WuXi Biologics and AC Immune SA announced the first steps of an exclusive strategic collaboration that covers biologics discovery, development and manufacturing.

WuXi Biologics signed exclusive research agreement with Brii Biosciences

r&d
WuXi Biologics, a leading global open-access biologics technology platform company, announced a strategic collaboration with Brii Bioscience.

Wuxi Biologics starts a drug development collaboration with ABL Bio

drug-development
WuXi Biologics and ABL Bio Corporation announced that the companies have entered into an exclusive development and clinical manufacturing partnership.

WuXi Biologics to construct a new biologics manufacturing facility

wuxi-biologics
WuXi Biologics (China) announced that it has commenced the construction of a Biologics Manufacturing Center of excellence, in the city of Shijiazhuang, one hour train from Beijing.

WuXi Biologics became an exclusive GMP manufacturing partner for Inhibrx

wuxi-biologics
WuXi Biologics and Inhibrx announced that the companies have entered into an exclusive partnership for the GMP manufacturing of certain of Inhibrx’s protein-based therapeutics.

WuXi Biologics successfully completed the first run of its MFG3 facility

wuxi-biologics
WuXi Biologics, a leading global open-access biologics technology platform company, announced that the first GMP campaign in the new MFG3 facility was completed successfully.

WuXi Biologics and Harbour BioMed entered a manufacturing partnership

molecules pic
WuXi Biologics and Harbour BioMed announced an initial strategic collaboration for the development and manufacturing of Harbour’s leading HCAb antibody.

WuXi Biologics will build a new manufacturing facility in USA

pharmaceutical manufacturing
WuXi Biologics announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts (USA).

WuXi Biologics and Tsinghua University Innovation Center starts a partnership

biologics
WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy, announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in discovery, development and manufacturing of biologics.